Project Grant R43HL180283
Award Date 9/24/25
Completion Date 3/23/26
Dollars Obligated $307K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded Dynocardia, Inc. a $499,881 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to complete the verification and validation (V&V) of their production-grade Vitrack hospital device. Vitrack is a wrist-wearable, cuff-less device that utilizes proprietary optomechanical sensor and computer vision technology to provide accurate, continuous, and non-invasive blood pressure monitoring, overcoming...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $349,734 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Actiox LLC, a biomedical technology company in Thousand Oaks, California. The project aims to develop a wearable microneedle-based biosensor for continuous, real-time cardiac troponin I monitoring. The goal is to demonstrate the feasibility of this transformative biosensor technology to enable earlier detection of ischemic events and...
- Vena Vitals Inc. received a $256,000 Project Grant award from the National Science Foundation on February 15, 2021 to support development of a beat-to-beat blood pressure monitor using micro-nanoscale wrinkled functional materials. The award is being used to fund research and development activities through December 31, 2022 under the NSF's Engineering program (CFDA 47.041). This program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,107,749 in funding to Invia LLC to develop deep learning tools for widely-available, inexpensive diagnosis of coronary microvascular and vasomotor dysfunction. The award commenced on September 5, 2025 and is scheduled for completion on August 31, 2027. The grant aims to foster research across basic, translational, clinical, and population sciences to...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $322,277 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Linshom Medical, Inc. in Baltimore, Maryland. The grant will fund clinical development activities focused on demonstrating the health economic value of Linshom's Continuous Predictive Respiratory Monitoring (CPRM) system. The CPRM system aims to reduce morbidity and mortality due to respiratory compromise while lowering healthcare costs...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $310,948 Project Grant to Minnesota Healthsolutions Corporation, a for-profit woman-owned small business, on September 15, 2023. The grant funds the development of an adaptable platform to support patients with behavior change interventions aimed at improving adherence to treatment and prevention for multiple chronic diseases. The platform will utilize remote...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,153 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Safebeat RX Inc. The funding supports the development of a novel, smartwatch-enabled technology that allows patients with low-risk atrial fibrillation to safely initiate antiarrhythmic medications at home. The technology analyzes post-drug ECG data taken by patients using a machine learning algorithm and provides this information to...
- The U.S. National Heart, Lung, and Blood Institute, through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $406,221 Project Grant to the Florida Institute of Technology Inc. (Florida TECH) on September 15, 2025. The grant supports the development of a novel, low-cost, machine learning-based and wearable technology for continuous monitoring of heart failure parameters, such as left ventricular function. The project aims to address the gap in remote cardiac...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $816,472 project grant to the Icahn School of Medicine at Mount Sinai (ISMMS). The grant, awarded on August 1, 2025 and set to conclude on May 31, 2029, aims to enhance cardiovascular risk prediction and treatment response in obstructive sleep apnea (OSA) patients using advanced AI-based transformer models and multi-modal sleep data. The project will...